截至 2026-09-30(2026-11-16 向 SEC 提交的 13F),Farallon Capital(法拉龙资本) 管理的 Tom Steyer 创立(汤姆·斯泰尔 创立) 披露 112 只美股持仓,申报总市值 $23.21B。前五大持仓:RVMD 14.8%、WBD 8.2%、NTRA 5.8%、BBIO 5.0%、PTGX 4.9%。本期变化:新建仓 ROKU、CRH、ASBH、IOND、LBRX、IMCR、ASML、BABA、ETRA、INDV;清仓 EA、CRINETICS PHAR、APOGEE THERAPE、NVO、MRK、WRBY、AXTA、BBNX、SMG、WAY;主要加仓 WBD、ROIV、BBIO、NTRA、BIIB;主要减仓 TMO、LNTH、TNGX、MSFT、UNH。
法拉龙资本(Farallon Capital)1986 年由汤姆·斯泰尔(Tom Steyer)在旧金山创立,斯泰尔 2012 年离开,现由管理合伙人团队管理。多策略:并购套利、事件驱动、信贷、地产与股票。13F 是机构股票多头的汇总,含期权,不代表某一策略或个人观点。
| # | 代码 | 公司 | 权重 | 市值 | 股数 | 本期 |
|---|---|---|---|---|---|---|
| 1 | RVMD | Revolution Medicines, Inc. | 14.8% | $2.75B | 13,418,796 | 减仓 |
| 2 | WBD | Warner Bros. Discovery Inc | 8.2% | $1.53B | 49,372,344 | 加仓 |
| 3 | NTRA | Natera, Inc. | 5.8% | $1.07B | 2,599,648 | 加仓 |
| 4 | BBIO | BridgeBio Pharma, Inc. | 5.0% | $937.45M | 14,247,000 | 加仓 |
| 5 | PTGX | Protagonist Therapeutics, Inc. | 4.9% | $907.04M | 6,437,906 | 加仓 |
| 6 | EXEL | Exelixis, Inc. | 4.6% | $858.33M | 14,694,910 | 加仓 |
| 7 | ROIV | Roivant Sciences Ltd. | 4.3% | $795.23M | 21,745,533 | 加仓 |
| 8 | ROKU | Roku, Inc. | 3.4% | $633.49M | 4,160,049 | 建仓 |
| 9 | AMZN | Amazon.com, Inc. | 3.2% | $590.10M | 2,368,464 | 减仓 |
| 10 | GRAL | GRAIL, Inc. | 3.1% | $570.18M | 4,069,233 | 减仓 |
| 11 | BSX | Boston Scientific Corporation | 2.6% | $492.68M | 11,287,164 | 加仓 |
| 12 | AVGO | Broadcom Inc. | 2.6% | $490.19M | 1,395,810 | 加仓 |
| 13 | CRH | CRH plc | 2.4% | $442.24M | 5,341,100 | 建仓 |
| 14 | KVUE | Kenvue Inc | 2.4% | $441.76M | 25,015,000 | 持有 |
| 15 | TWST | Twist Bioscience Corporation | 2.2% | $412.84M | 2,136,400 | 持有 |
| 16 | UNH | UnitedHealth Group Incorporated | 2.1% | $384.93M | 1,048,622 | 减仓 |
| 17 | MSFT | Microsoft Corporation | 2.0% | $376.24M | 733,563 | 减仓 |
| 18 | SNPS | Synopsys, Inc. | 2.0% | $373.13M | 857,890 | 加仓 |
| 19 | KKR | KKR & Co. Inc. | 1.9% | $354.25M | 3,880,020 | 减仓 |
| 20 | AON | Aon plc | 1.8% | $343.10M | 1,239,672 | 减仓 |
| 21 | LNTH | Lantheus Holdings, Inc. | 1.7% | $309.66M | 3,111,254 | 减仓 |
| 22 | TMO | Thermo Fisher Scientific Inc. | 1.6% | $300.86M | 445,685 | 减仓 |
| 23 | LQDA | Liquidia Corporation | 1.4% | $269.50M | 8,906,038 | 加仓 |
| 24 | WAB | Westinghouse Air Brake Technologies Corporation | 1.4% | $252.12M | 877,903 | 减仓 |
| 25 | BEAM | Beam Therapeutics Inc. | 1.3% | $251.26M | 10,276,396 | 加仓 |
| 26 | ARMK | Aramark | 1.3% | $246.67M | 4,606,431 | 加仓 |
| 27 | IMVT | Immunovant, Inc. | 1.2% | $218.59M | 6,471,000 | 加仓 |
| 28 | AGIO | Agios Pharmaceuticals, Inc. | 1.1% | $197.49M | 5,939,400 | 加仓 |
| 29 | BIIB | Biogen Inc. | 0.8% | $153.79M | 680,868 | 加仓 |
| 30 | JNJ | Johnson & Johnson | 0.7% | $127.19M | 480,426 | 加仓 |
数据来源:SEC EDGAR 13F-HR 公开申报。13F 只披露季度末的美股多头仓位,提交期限为季度结束后 45 天,不含空头、现金和非美股资产;不构成投资建议。 原始申报:SEC EDGAR 0000908834-26-000540。 机器可读数据:farallon.json。